Torque Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Torque Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress…

1986-11-20 Chandigarh, Chandigarh Active Unlisted Active Compliant
Share
Connect MCP
TP Torque Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Torque Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Torque Pharmaceuticals is assessed as Low Risk with a Trust Score of 82/100. Torque Pharmaceuticals is an active private limited indian non-government company incorporated in 1986, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 25 Jul 2026 from the latest processed filings. Torque Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Neutral

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (A3).

Charges position: 15 open (266.02 cr) · 18 satisfied (68.04 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited5 48.0 cr
State Bank Of India4 48.0 cr
Small Industries Development Bank Of India12 48.0 cr
Sidbi1 48.0 cr
Tata Capital Financial Services Limited2 48.0 cr
Axis Bank Limited4 48.0 cr
Compliance Score: 50/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 3 court forum(s).
  • 2 auditor resignation(s) filed - latest: S KUMAR GUPTA & ASSOCIATES on 2022-08-20.
  • Delayed payments to MSME suppliers disclosed (18 disclosure(s)).
  • 20 active GST registration(s).
Legal cases on record (3)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MANDEEP SINGH 01234567 Director 01/04/2018 6 yrs Approved
AMARIQBAL SINGH BEDI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
0 allotment(s) · 3 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
Filmy Keeda Productions Private Limited Subsidiary Company 74.00%

Key managerial personnel: AMARIQBAL SINGH BEDI (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 39+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (50/100).
15 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 18.47 Lakh.
3 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 15 open charge(s) of 266.02 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
25 Mar 2025
Charge created
Hdfc Bank Limited - 17.00 cr
30 Nov 2024
Last AGM held
Annual general meeting
31 Mar 2024
Share transfer (FY 2024)
53834.00000000 shares to TARUNPREET
Latest balance sheet
Filed with ROC
30 Apr 2023
Charge created
Axis Bank Limited - 79.89 Lakh
31 Mar 2023
Share transfer (FY 2023)
161501.00000000 shares to MANDEEP SINGH
10 Feb 2023
Charge created
Axis Bank Limited - 1.49 cr
15 Nov 2022
Director ceased
AMARIQBAL SINGH BEDI
05 Nov 2022
Director appointed
MANDEEP SINGH (Director)
18 Oct 2022
Director ceased
PARAMJIT SINGH CHHATWAL
06 Jun 2022
Charge created
State Bank Of India - 6.55 cr
31 Mar 2022
Share transfer (FY 2022)
1500.00000000 shares to AMAR IQBAL SINGH
23 Feb 2022
Charge created
Axis Bank Limited - 2.20 cr
28 Jan 2022
Charge created
Tata Capital Financial Services Limited - 2.00 cr
19 Jan 2022
Charge created
Hdfc Bank Limited - 80.00 Lakh
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
20 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A3 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Kopl U85110KA1991PLC012095 Bangalore, Karnataka, India
Panacea Biotec L33117PB1984PLC022350 Lalru, Punjab, India
Hetero Biopharma U24290TG2016PLC111946 Balanagar, Telangana, India
Skymap U24233DL2006PTC150088 New Delhi, Delhi, India
Unicure India Ltd U74899DL1980PLC010642 New Delhi, Delhi, India
Aristo Laboratories Private Limited U24110MH1980PTC266205 Mumbai, Maharashtra, India
Lords Mark U21001MH1998PLC115601 Mumbai, Maharashtra, India
Milan Laboratories (India) U24230MH2003PTC139736 Thane, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Torque Pharmaceuticals before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Torque Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Torque Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Torque Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Torque Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Torque Pharmaceuticals an active company?

Torque Pharmaceuticals has MCA status “Active” with a compliance score of 50/100 (Moderate).

Is Torque Pharmaceuticals financially healthy?

Torque Pharmaceuticals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Torque Pharmaceuticals?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Torque Pharmaceuticals?

Promoters hold a majority stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Torque Pharmaceuticals have loans or charges against its assets?

15 open charge(s) are registered against its assets, and 18 earlier charge(s) stand satisfied.

Is Torque Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 50/100 (Moderate).

Is it risky to lend to Torque Pharmaceuticals?

Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.